Autopsy report · NCT01940796

Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)

“Toxicity”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 2 months before it stopped.
• 19 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Massachusetts General Hospital

Sponsor type

University, hospital or other

Conditions

Graft-vs-Host Disease; GVHD

Interventions

Brentuximab Vedotin

Participants

19

Sites

1

Countries

United States

Trials that died the same way

• A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
  “Extreme toxicity” (89% match in meaning)
• Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
  “Inadequate toxicity” (88% match in meaning)
• In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
  “Dose Limiting Toxicities” (69% match in meaning)
• GFM-Acadesine: A Phase I-II Trial of Acadesine
  “Renal toxicity” (67% match in meaning)
• Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
  “Extreme toxicity in Phase I, study did not proceed to Phase II” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.